Home Business EU to order Illumina to divest Grail after blocking takeover

EU to order Illumina to divest Grail after blocking takeover

7 min read
Comments Off on EU to order Illumina to divest Grail after blocking takeover

Article content

BRUSSELS — EU antitrust regulators plan to order U.S. life sciences firm Illumina to divest biotechnology company Grail after an EU veto of the $7.1 billion acquisition over concerns it would hurt competition and stifle innovation.

The European Commission, which acts as the competition enforcer in the 27-country bloc, said on Tuesday that Illumina’s remedies did not adequately address its concerns, confirming a Reuters story in July.

Article content

Illumina completed the deal in August last year ahead of EU regulatory approval, resulting in an EU order to keep Grail separate and appoint independent managers to run the company until the investigation’s conclusion.

Advertisement 2

Article content

“With this transaction, Illumina would have an incentive to cut off Grail’s rivals from accessing its technology, or otherwise disadvantage them,” EU antitrust chief Margrethe Vestager said in a statement.

“It is vital to preserve competition between early cancer detection test developers at this critical stage of development. As Illumina did not put forward remedies that would have solved our concerns, we prohibited the merger,” she said.

Illumina said it would challenge the EU veto.

“To prepare for the anticipated divestment order from the European Commission in the coming months, the company will begin reviewing strategic alternatives for GRAIL in the event the divestiture is not stayed pending Illumina’s appeal,” it said in a statement.

Advertisement 3

Article content

The EU watchdog said Illumina offered to give a license for its NGS (next generation sequencing) patents to some NGS suppliers, with provisions in agreements valid until 2033. It also offered a three-year patent truce with Chinese rival BGI Genomics.

Illumina is already in talks with the Commission to divest Grail, people familiar with the matter told Reuters on Monday.

Illumina scored a victory last week when a U.S. administrative judge backed its challenge against a lawsuit by the Federal Trade Commission (FTC) against the deal. The FTC has said it will appeal.

Separately, Illumina faces an EU fine of as much as 10% of its annual global turnover for jumping the gun and has set aside $453 million for this.

The deal would have given Illumina access to Grail’s flagship Galleri blood test used to diagnose cancers at early stages when the disease is easier to treat. (Reporting by Foo Yun Chee; editing by Philip Blenkinsop)



Postmedia is committed to maintaining a lively but civil forum for discussion and encourage all readers to share their views on our articles. Comments may take up to an hour for moderation before appearing on the site. We ask you to keep your comments relevant and respectful. We have enabled email notifications—you will now receive an email if you receive a reply to your comment, there is an update to a comment thread you follow or if a user you follow comments. Visit our Community Guidelines for more information and details on how to adjust your email settings.

Source link

Load More Related Articles
Load More By 
Load More In Business
Comments are closed.

Check Also

year JGB yield falls, longer-term notes keep rising

Article content TOKYO — The Japanese government bond market moved in mixed directions on W…